Company news
LeonaBio, Inc. news in 2026
LeonaBio, Inc.'s news releases, calls and decks from 2026, newest first.
LeonaBio to Participate in Cantor Global Healthcare Conference 2026
September 3, 2026
LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology’s 4th Summit on Breast Cancer
August 12, 2026
LeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development Summit
June 3, 2026
LeonaBio to Participate in Upcoming Medical and Industry Meetings in June
May 26, 2026
LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D.
May 7, 2026
LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer
April 23, 2026
Independent Nonclinical Research on Lasofoxifene Presented at American Association for Cancer Research Annual Meeting 2026 Consistent with LeonaBio’s Data
April 21, 2026
LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update
March 25, 2026
LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer
February 2, 2026
Decks in 2026
- Investor Presentation (August 2026)
Investor deck · 36 slides · August 2026
- Investor Presentation (March 2026)
Investor deck · 41 slides · Mar 26, 2026